Alain Moussy, AB Science

Clin­i­cal stud­ies for AB Sci­ence's all-pur­pose an­ti-in­flam­ma­to­ry drug grind to a halt as com­pa­ny flags po­ten­tial risk of heart dis­ease

When AB Sci­ence claimed a break­out win in Alzheimer’s dis­ease for ma­sitinib, its all-pur­pose ty­ro­sine ki­nase in­hibitor, in late De­cem­ber, CEO Alain Moussy point­ed End­points News to safe­ty da­ta across thou­sands of pa­tients as a key strength of the pro­gram — which has seen its share of set­backs and reg­u­la­to­ry scorn over the years.

“We have a re­mark­able safe­ty data­base of co-mor­bidi­ties in every di­rec­tion and we feel ex­treme­ly strong on the safe­ty side be­cause we have ex­posed so many pa­tients,” he said in an in­ter­view then.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.